Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 3/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SI | P14410 | 3/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16035881 | 0.82 | RAB9A (0.60) | RAB9ASMN1; SMN2TSHRNPC1MAPT | |
| SCHEMBL678640 | 0.78 | RAB9A (1.00) | RAB9ASMN1; SMN2TSHRNPC1MAPT | |
| SCHEMBL30355239 | 0.78 | RAB9A (1.00) | RAB9ASMN1; SMN2TSHRNPC1MAPT | |
| SCHEMBL15430860 | 0.77 | RAB9A (0.58) | RAB9ANPSR1GAASMN1; SMN2TSHR | |
| SCHEMBL23619041 | 0.77 | RAB9A (0.67) | RAB9ASMN1; SMN2TSHRKDM4ENPC1 | |
| SCHEMBL10452441 | 0.77 | NPC1 (0.58) | RAB9ANPSR1MGAMAMY1AGAA | |
| SCHEMBL27314207 | 0.74 | RAB9A (0.54) | RAB9ASMN1; SMN2TSHRMAPTALDH1A1 | |
| SCHEMBL16036700 | 0.73 | RAB9A (0.71) | RAB9ASMN1; SMN2TSHRKDM4ENPC1 | |
| SCHEMBL12628808 | 0.72 | KDM4E (0.46) | NPSR1SMN1; SMN2TSHRKDM4ENPC1 | |
| SCHEMBL12922843 | 0.68 | CYP17A1 (0.49) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858622-B2 | Cycloalkano-indole and -azaindole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-02-22 | — | — | US | disclosed |
| CN-1183111-C | Cycloalkano-indote and againdole derivatives, process for their preparation and pharmaceutical composition containing the same | — | 2005-01-05 | — | — | CN | disclosed |
| EP-0705831-B1 | Cycloalkano-indole- and -azaindole derivatives | BAYER AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030149073-A1 | Cycloalkano-indole and -azaindole derivatives | MULLER ULRICH (DE) | 2003-08-07 | — | — | US | disclosed |
| US-6479503-B2 | SUCH AS 2-(S/R)-2-(4-(2,4-DIMETHYL-5,6,7,8-TETRAHYDRO-ALPHA-CARBOLIN-9-YL)METHYL -PHENYL)-2-CYCLOPENTYL-ACETIC ACID N-((R)PHENYLGLYCINOAMIDE) FOR TREATING ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | MUELLER ULRICH (DE) | 2002-10-10 | — | — | US | disclosed |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | MULLER ULRICH (DE) | 2002-05-09 | — | — | US | disclosed |
| US-6265431-B1 | ANTICHOLESTEROL DRUGS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-24 | — | — | US | disclosed |
| US-6245775-B1 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-12 | — | — | US | disclosed |
| US-5684014-A | FOR TREATING ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0705831-A2 | Cycloalkano-indole- and -azaindole derivatives | BAYER AG (DE) | 1996-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149073-A1 | Cycloalkano-indole and -azaindole derivatives | AADAC, IDO1, AADAT | RAB9A 4444/4885NPSR1 760/4885MGAM 1099/4885 |
| US-20020147209-A1 | Cycloalkano-indole and -azaindole derivatives | AADAC, IDO1, AADAT | RAB9A 4444/4885NPSR1 760/4885MGAM 1099/4885 |
| US-20020055635-A1 | Cycloalkano-indole and -azaindole derivatives | ADRB3, AADAT, INMT | RAB9A 3996/4885NPSR1 522/4885MGAM 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.